RxSight Faces Multiple Downgrades Amid Revenue Shortfall

RxSight shares are trading lower after Piper Sandler, BofA Global Research, and Wells Fargo all downgraded the stock, cutting their price targets to $10, $9, and $9 respectively, following the company's lower-than-expected Q2 results and reduced FY25 guidance.